GlassScriptPhysician profile
Andrew S Lai
NPI 1003983958
$2,663.46
in general payments reported to CMS, 2019-2025
27 companies · $828 in 2025
The $828 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $110 · 2022: $179 · 2023: $308 · 2024: $543 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $326.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $323.06 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $228.12 | 2023-2025 | |
| Pfizer INC. | $222.60 | 2019-2025 | |
| Abbvie INC. | $219.00 | 2019-2024 | |
| Novo Nordisk INC | $191.14 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $165.32 | 2019-2024 | Andexxa, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $127.60 | 2019-2020 | |
| Axsome Therapeutics, INC. | $121.79 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $115.31 | 2019-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $95.57 | 2019-2025 | Spravato |
| Exact Sciences Corporation | $64.13 | 2025 | |
| Astellas Pharma US INC | $63.70 | 2020-2025 | Veozah |
| Esperion Therapeutics, INC. | $62.29 | 2024 | Nexlizet, Nexletol |
| Becton, Dickinson and Company | $53.00 | 2024 | Site-Rite |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.98 | 2022 | |
| Verity Pharmaceuticals INC. | $34.80 | 2025 | Tlando |
| Viiv Healthcare Company | $34.43 | 2025 | Apretude |
| Allergan, INC. | $29.99 | 2019 | |
| Dexcom, INC. | $28.13 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $22.33 | 2025 | Symplicity G3 |
| Bausch Health US, LLC | $19.84 | 2025 | Aplenzin |
| Phathom Pharmaceuticals, INC. | $19.34 | 2024 | Voquezna |
| Antares Pharma, INC. | $16.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2020 | |
| Intra-Sana Laboratories | $14.19 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Duchesnay USA Incorporated | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.